|
|
|
|
|
|
|
Education: Post-doctoral Training St. Jude Children’s Research Hospital , Post-Doctoral Fellow in Pharmacometrics/Immunotherapy (1987-1990) Graduate Training Philadelphia College of Pharmacy & Science, Pharm.D. (1987) Tampa VA Medical Center , Hospital Pharmacy Residency (1983-1984) Undergraduate Training West Virginia University School of Pharmacy, B.S. Pharmacy (1983) Practice Interests: Hematology & Oncology
Research Interests: Clinical drug development in oncology
Selected Recent Publications: Petros WP , Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks J. Associations between variants in several drug metabolism genes, chemotherapy pharmacokinetics and clinical anti-cancer response. In press, J Clin Oncol. Petros WP & Evans WE. Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharm Sci 2004;25:457-464. Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP , Garbriel D, Serody J, Kirby S, Wiley J. Intra-individual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: Assessment of a test dose and first dose strategy . Anti-Cancer Drugs 2004;15:453-459 . Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP , Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI. . A phase I trial of preoperative 5-fluorouracil plus eniluracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. Int J Radiat Oncol Biol Phys 2004;58:779-85. Cheng TY, Grubbs E, Abdul-Wahab O, Leu SY, Hung CF, Petros W , Aloia T, Fedrau R, Pruitt S, Colvin M, Friedman H, Tyler D. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg. 2003 Nov;186(5):460-7. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, OvermoyerB, Makkar V, Stambler B, Taylor A, Waas J, Lewin J, McCrae KR, Remick SC. A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A4 Phosphate (CA4P) on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer. Cancer Res 2002;62:3408-3416. Petros WP , Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP. Association of high-dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with response, toxicity and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002;8:698-705. Rizzieri D, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP , Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO. Phase I evaluation of continuous-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 2002;20:674-679. Martell RE, Peterson B, Cohen HJ, Petros W, Rai KR, Larson R, Schiffer C, Elias L, Sheperd L, Hurwitz HI. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: A CALGB (9011) coordinated Intergroup Study. Cancer Chemother Pharmacol 2002;50:37-45. Professional Memberships: American Association for Cancer Research |
||||
